Please assess the completion status of the following clinical trial:

Trial Title: Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed stage IV bladder carcinoma that is unlikely to respond to existing therapy and for which no curative therapy exists or stage IV newly diagnosed, incurable bladder carcinoma~* Measurable disease by CT scan~* Tumor must be greater than 2 cm at the largest diameter for the lymph nodes located in the head, neck, axillary, inguinal, or femoral areas and at least 0.5 cm in the largest diameter for other localizations~* 18 and over~* Karnofsky 60-100%~* Life expectancy: greater than 2 months~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~* Bilirubin no greater than 2.5 mg/dL~* SGOT/SGPT no greater than 5 times upper limit of normal~* No hepatic failure~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~* No severe heart disease~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~* No severe lung disease~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No serious active infections or fever~* No other serious concurrent disease~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulating agents~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* Concurrent corticosteroids allowed~* At least 8 weeks since prior radiotherapy and recovered~* Recovered from any prior operative procedure~* Prior cytodifferentiating agent allowed~Exclusion Criteria:~- Prior antineoplaston therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplastons (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).